Altstiel LD - Search Results

1

Barriers to drug discovery and development for Alzheimer disease.

Fillit HM, O'Connell AW, Brown WM, Altstiel LD, Anand R, Collins K, Ferris SH, Khachaturian ZS, Kinoshita J, Van Eldik L, Dewey CF. Fillit HM, et al. Among authors: altstiel ld. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S1-8. doi: 10.1097/00002093-200200001-00001. Alzheimer Dis Assoc Disord. 2002. PMID: 12070355 Review.

2

Barriers to Alzheimer disease drug discovery and development in the biotechnology industry.

Altstiel LD. Altstiel LD. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S29-32. doi: 10.1097/00002093-200200001-00005. Alzheimer Dis Assoc Disord. 2002. PMID: 12070359 Review.

3

Elevated circulating tumor necrosis factor levels in Alzheimer's disease.

Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G. Fillit H, et al. Neurosci Lett. 1991 Aug 19;129(2):318-20. doi: 10.1016/0304-3940(91)90490-k. Neurosci Lett. 1991. PMID: 1745413

4

Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease.

Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Burstein AH, et al. J Prev Alzheimers Dis. 2018;5(2):149-154. doi: 10.14283/jpad.2018.18. J Prev Alzheimers Dis. 2018. PMID: 29616709 Review.

5

A pilot study of prednisone in Alzheimer's disease.

Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL. Aisen PS, et al. Dementia. 1996 Jul-Aug;7(4):201-6. doi: 10.1159/000106879. Dementia. 1996. PMID: 8835883 Clinical Trial.

6

Cytokines in Alzheimer's disease.

Altstiel LD, Sperber K. Altstiel LD, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(4):481-95. doi: 10.1016/0278-5846(91)90023-t. Prog Neuropsychopharmacol Biol Psychiatry. 1991. PMID: 1749826

7

Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients.

Altstiel LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P, Davis K. Altstiel LD, et al. Dementia. 1995 Jan-Feb;6(1):17-20. doi: 10.1159/000106917. Dementia. 1995. PMID: 7728215

8

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.

Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, Altstiel LD. Schwam EM, et al. Among authors: altstiel ld. Curr Alzheimer Res. 2014;11(5):413-21. doi: 10.2174/1567205011666140505100858. Curr Alzheimer Res. 2014. PMID: 24801218 Clinical Trial.

9

Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis.

Burstein AH, Brantley SJ, Dunn I, Altstiel LD, Schmith V. Burstein AH, et al. Among authors: altstiel ld. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. doi: 10.1002/cpdd.689. Epub 2019 Apr 1. Clin Pharmacol Drug Dev. 2019. PMID: 30934161

10

Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old.

Gabriel SM, Marin DB, Aisen PS, Lantz M, Altstiel LD, Davis KL, Mohs RC. Gabriel SM, et al. Among authors: altstiel ld. Am J Psychiatry. 1998 May;155(5):698-700. doi: 10.1176/ajp.155.5.698. Am J Psychiatry. 1998. PMID: 9585727

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page